This sugar kills honeybees—it could also help fight cancer

(Press-News.org) LA JOLLA, CALIF. – July 18, 2023 –Research from Sanford Burnham Prebys and the Osaka International Cancer Institute has shed new light on the anti-cancer properties of mannose, a sugar that is crucial to many physiological processes in humans and is also known to inhibit the growth of cancer cells. The findings, published in the journal eLife, suggest that mannose could be a helpful secondary treatment for cancer.

“This sugar could give cancer an extra punch alongside other treatments,” says study co-author Hudson Freeze, Ph.D., director of the Human Genetics Program at Sanford Burnham Prebys. “And because mannose is found throughout the body naturally, it could improve cancer treatment without any undesirable side effects.”

Mannose is a sugar that the body adds to proteins to stabilize their structure and help them interact with other molecules. This process, called glycosylation, is essential for life; and malfunctions in glycosylation are associated with rare, but often life-threatening, human diseases.

“Until now, the most promising therapeutic use for mannose was to treat congenital disorders of glycosylation, diseases that can cause a wide range of severe symptoms throughout the body,” says Freeze. “But we believe that there may be ways to leverage mannose against cancer and other diseases as well.”

Mannose has already been shown to inhibit the growth of several types of cancer in the lab, but scientists don’t fully understand why this happens. To learn more, the research team turned their attention to an unusual property of mannose observed in an unlikely subject: honeybees. 

“It’s been known for more than a century that mannose is lethal to honeybees because they can’t process it like humans do—it’s known as ‘honeybee syndrome,’” says Freeze. “We wanted to see if there is any relationship between honeybee syndrome and the anti-cancer properties of mannose, which could lead to an entirely new approach to combat cancer.” 

Using genetically engineered human cancer cells from fibrosarcoma—a rare cancer that affects connective tissue—the research team re-created honeybee syndrome and discovered that without the enzyme needed to metabolize mannose, cells replicate slowly and are significantly more vulnerable to chemotherapy. 

“We found that triggering honeybee syndrome in these cancer cells made them unable to synthesize the building blocks of DNA and replicate normally,” says Freeze. “This helps explain the anti-cancer effects of mannose that have we’ve observed in the lab.” 

While leveraging honeybee syndrome could be a promising supplemental cancer treatment, the researchers caution that because the effect is dependent on vital metabolic processes, more research is needed to determine which types of cancer would be most vulnerable to mannose.

“If we can find cancers that have a low activity of the enzyme that processes mannose, treating them with mannose could give just enough of a nudge to make chemotherapy more effective,” says Freeze. “Many people assume that you always discover treatments in response to the disease, but sometimes you find biology that could be useful for treatment and then have to find the disease to match it.”

In the meantime, the study speaks to the broader potential of glycosylating sugars for cancer treatment, which is still an emerging area of research. 

“The glycobiology of sugar metabolism within cancer cells is still an unexplored frontier, and it could be an untapped treasure trove of potential treatments just waiting to be discovered,” adds Freeze. 

###

Additional authors on the study include Yoichiro Harada, Yu Mizote, Toru Hiratsuka, Yusuke Imagawa, Kento Maeda, Yuki Ohkawa, Shigeki Higashiyama, Hideaki Tahara and Naoyuki Taniguchi, Osaka International Cancer Institute; Takehiro Suzuki and Naoshi Dohmae, RIKEN Center for Sustainable Resource Science; Akiyoshi Hirayama, Satsuki Ikeda and Junko Murai, Keio University; Mikako Nishida and Heiichiro Udono, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences; and Ayaka Ueda and Eiji Miyoshi, Osaka University. 

The study was supported by the Takeda Science Foundation, JSPS KAKENHI (JP23K06645), the Rocket Fund, and the National Institutes of Health (R01DK99551).

The study’s DOI is 10.7554/eLife.83870.

About Sanford Burnham Prebys

Sanford Burnham Prebys is an independent biomedical research institute dedicated to understanding human biology and disease and advancing scientific discoveries to profoundly impact human health. For more than 45 years, our research has produced breakthroughs in cancer, neuroscience, immunology and children’s diseases, and is anchored by our NCI-designated Cancer Center and advanced drug discovery capabilities. For more information, visit us at SBPdiscovery.org or on Facebook facebook.com/SBPdiscovery and on Twitter @SBPdiscovery.

END